Last reviewed · How we verify
Satraplatin in combination with Paclitaxel
Satraplatin in combination with Paclitaxel is a Small molecule drug developed by Agennix. It is currently in Phase 2 development.
At a glance
| Generic name | Satraplatin in combination with Paclitaxel |
|---|---|
| Sponsor | Agennix |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers (PHASE1)
- Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Satraplatin in combination with Paclitaxel CI brief — competitive landscape report
- Satraplatin in combination with Paclitaxel updates RSS · CI watch RSS
- Agennix portfolio CI
Frequently asked questions about Satraplatin in combination with Paclitaxel
What is Satraplatin in combination with Paclitaxel?
Satraplatin in combination with Paclitaxel is a Small molecule drug developed by Agennix.
Who makes Satraplatin in combination with Paclitaxel?
Satraplatin in combination with Paclitaxel is developed by Agennix (see full Agennix pipeline at /company/agennix).
What development phase is Satraplatin in combination with Paclitaxel in?
Satraplatin in combination with Paclitaxel is in Phase 2.